Scarica l'app Stockscreener
2.14
2.28%
-0.05
Pre-mercato:
2.13
-0.01
-0.47%
Precedente Chiudi:
$2.19
Aprire:
$2.19
Volume 24 ore:
737.26K
Relative Volume:
0.51
Capitalizzazione di mercato:
$234.79M
Reddito:
-
Utile/perdita netta:
$-134.24M
Rapporto P/E:
-1.209
EPS:
-1.77
Flusso di cassa netto:
$-121.34M
1 W Prestazione:
-17.69%
1M Prestazione:
-7.76%
6M Prestazione:
-24.38%
1 anno Prestazione:
-64.27%
Intervallo 1D:
$2.10
$2.2297
Intervallo di 1 settimana:
$2.10
$2.60
Portata 52W:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Nome
Annexon Inc
Settore
Industria
Telefono
(650)-822-5500
Indirizzo
1400 SIERRA POINT PARKWAY, BRISBANE
Confronta ANNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.14 | 258.23M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-30 | Iniziato | Wells Fargo | Overweight |
| 2023-05-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | BTIG Research | Buy |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Annexon Inc Borsa (ANNX) Ultime notizie
Annexon Inc. Sees Relief Buying After Extended Drop2025 Macro Impact & Growth Focused Stock Reports - newsyoung.net
How to forecast Annexon Inc. trends using time series2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - Newser
What moving averages say about Annexon Inc.July 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - Newser
Developing predictive dashboards with Annexon Inc. dataMarket Trend Report & AI Enhanced Trading Signals - Newser
Is Annexon Inc. stock reversal real or fake2025 Risk Factors & Consistent Profit Trading Strategies - Newser
How hedge fund analytics apply to Annexon Inc. stockCEO Change & Weekly Market Pulse Updates - Newser
Will Annexon Inc. see short term momentumQuarterly Market Summary & Risk Managed Investment Strategies - Newser
How to use a screener to detect Annexon Inc. breakoutsQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Strategies to average down on Annexon Inc.2025 Growth vs Value & Daily Volume Surge Trade Alerts - Newser
Using AI based signals to follow Annexon Inc.2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Will breakout in Annexon Inc. lead to full recoveryJuly 2025 Intraday Action & Growth Focused Entry Point Reports - Newser
Can you recover from losses in Annexon Inc.2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - Newser
Can volume confirm reversal in Annexon Inc.Quarterly Trade Summary & Advanced Swing Trade Entry Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Applying Wyckoff theory to Annexon Inc. stockDividend Hike & Expert Approved Momentum Trade Ideas - Newser
Equity Incentive Trends in Biotech: Assessing Annexon's Recent Grant and Its Implications for Talent Retention and Growth - AInvest
Annexon Reports Inducement Grant to New Employee Under Nasdaq Li - GuruFocus
Annexon reports inducement grant to new employee under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
60,000 Share Options at $2.44: Annexon Grants Inducement Award Under Nasdaq Employment Plan - Stock Titan
Will Annexon Inc. stock go up soon2025 Breakouts & Breakdowns & Free Reliable Trade Execution Plans - Newser
Annexon Reports Q2 2025 Earnings Miss, Spikes Short-Term Gains Amid Volatility - AInvest
What makes Annexon Inc. stock attractive to long term investors2025 Momentum Check & Weekly Sector Rotation Insights - Newser
Annexon Inc's Q2 2025 EPS Beats Estimates, with Robust Cash Position and Strong Pipeline Progress - AInvest
Will Annexon Inc. benefit from macro trendsQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Signal strength of Annexon Inc. stock in tech scannersEarnings Growth Report & Risk Controlled Daily Plans - Newser
Will Annexon Inc. rebound enough to break evenPortfolio Update Summary & Free Weekly Watchlist of Top Performers - Newser
Using RSI to spot recovery in Annexon Inc.Market Weekly Review & Daily Volume Surge Signals - Newser
What machine learning models say about Annexon Inc.Weekly Stock Analysis & Free Weekly Watchlist of Top Performers - Newser
Is Annexon Inc. stock risky to hold nowMarket Movers & Risk Managed Trade Strategies - newsyoung.net
How Interest Rate Changes Impact Annexon Inc. Stock PerformanceGold Moves & Growth Focused Stock Pick Reports - Newser
Annexon Misses Q2 Earnings, Drives Short-Term Gains Amid Biotech Sector Resilience - AInvest
HC Wainwright Reaffirms “Buy” Rating for Annexon (NASDAQ:ANNX) - Defense World
Trend analysis for Annexon Inc. this weekJuly 2025 Retail & Technical Pattern Alert System - Newser
Annexon Biosciences Faces Financial Risks Amid Global Trade Challenges - MSN
Price momentum metrics for Annexon Inc. explainedBull Run & Safe Capital Growth Plans - Newser
Why Annexon Inc. stock attracts strong analyst attentionMarket Trend Review & Fast Gain Stock Tips - thegnnews.com
Applying sector rotation models to Annexon Inc.Portfolio Return Report & Low Volatility Stock Recommendations - Newser
Annexon Biosciences Receives Buy Rating and $14 Price Target from Wells Fargo Analyst - AInvest
Promising Outlook for Annexon Biosciences: Buy Rating Backed by Strong Pipeline and Financial Stability - TipRanks
Annexon Biosciences Reports Q2 2025 Financial Results - TipRanks
Regression Model Predicts Rangebound Movement in Annexon Inc.2025 Geopolitical Influence & Risk Controlled Stock Alerts - sundaytimes.kr
Annexon's Path to Commercialization: Assessing Clinical Milestones and Financial Viability in a High-Risk, High-Reward Biotech Play - AInvest
Annexon Narrows Loss in Fiscal Q2 - The Globe and Mail
Annexon Biosciences Q2 GAAP EPS of -$0.34 Beats Estimates - AInvest
Annexon Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annexon reports Q2 EPS (34c), consensus (36c) - TipRanks
Annexon's Strategic Momentum in 2025: Near-Term Catalysts and Long-Term Value Creation - AInvest
Annexon Reports Q2 2025 Financial Results and Highlights Portfolio Progress, Anticipated Milestones for Tanruprubart, Vonaprument, and ANX1502 - AInvest
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
How Annexon Inc. stock performs during market volatilityAnalyst Downgrade & Safe Capital Growth Plans - Newser
Annexon Inc Azioni (ANNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Annexon Inc Azioni (ANNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,116 |
2,879 |
105,084 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,117 |
2,882 |
121,616 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Jul 14 '25 |
Sale |
2.61 |
853 |
2,226 |
130,689 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):